Open AccessMoving Beyond Surrogate Endpoints in Cell Therapy Trials for Heart Disease
Author(s) -
Malliaras Konstantinos,
Marbán Eduardo
Publication year - 2014
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2013-0104
Subject(s) - surrogate endpoint , myocardial infarction , medicine , disease , ejection fraction , clinical trial , clinical endpoint , heart failure , cardiology , intensive care medicine
Studies of cell therapy for heart disease have generally been underpowered, with an emphasis on low‐risk patients who have suffered a myocardial infarction. The focus has been on surrogate endpoints (such as ejection fraction) rather than on major clinical events. This article argues in favor of targeting higher‐risk populations in which there is some expectation of being able to influence mortality or rehospitalization.